anmelden
Vistin Pharma ASA: New CEO appointed
Werte in diesem Artikel
Oslo, Norway, 25th of October 2023
The Board of Directors of Vistin Pharma ASA has appointed Magnus Tolleshaug as the new CEO of Vistin Pharma from 1st of January 2024. Magnus Tolleshaug is currently the CCO in Vistin Pharma, and will replace the current CEO, Kjell-Erik Nordby. Kjell-Erik has been the CEO of Vistin Pharma since the company was established in 2015 and has decided to retire. Magnus started his career in Vistin 1st of March 2020 and has been instrumental in delivering Vistin’s ambitious growth strategy. Before Magnus joined Vistin, he worked for many years in Takeda Pharmaceuticals as «Head of Global Launch Excellence & Product Lifecycle Management». Magnus has more than 20 years of experience from the global pharmaceutical industry and various international leadership roles.
During Kjell-Erik’s leadership Vistin’s Metformin business has seen more than 300% revenue growth and he has been essential in transforming Vistin into a well-recognized world leading Metformin producer.
*****
For further information, please contact:
Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Ausgewählte Hebelprodukte auf Vistin Pharma ASA
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Vistin Pharma ASA
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Vistin Pharma ASA Aktie News
Vistin Pharma ASA Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Vistin Pharma ASA nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
Keine Analysen gefunden.
